Droloxifene (original) (raw)
Droloxifene (INN, USAN) (former developmental code names FK-435, ICI-79280, K-060, K-21060E, RP-60850), also known as 3-hydroxytamoxifen, is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group that was developed originally in Germany and later in Japan for the treatment of breast cancer, osteoporosis in men and postmenopausal women, and cardiovascular disorders but was abandoned and never marketed. It reached phase II and phase III clinical trials for these indications before development was discontinued in 2000. The drug was found to be significantly less effective than tamoxifen in the treatment of breast cancer in two phase III clinical trials.
| Property | Value |
|---|---|
| dbo:abstract | Droloxifene (INN, USAN) (former developmental code names FK-435, ICI-79280, K-060, K-21060E, RP-60850), also known as 3-hydroxytamoxifen, is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group that was developed originally in Germany and later in Japan for the treatment of breast cancer, osteoporosis in men and postmenopausal women, and cardiovascular disorders but was abandoned and never marketed. It reached phase II and phase III clinical trials for these indications before development was discontinued in 2000. The drug was found to be significantly less effective than tamoxifen in the treatment of breast cancer in two phase III clinical trials. Droloxifene is an analogue of tamoxifen, specifically 3-hydroxytamoxifen, but has been said to have 10- to 60-fold increased affinity for the estrogen receptor and reduced partial estrogen agonistic activity. The affinity of droloxifene for the estrogen receptor ranges from 0.2 to 15.2% relative to estradiol in different studies. For comparison, the ranges are 0.06 to 16% for tamoxifen and 0.1 to 12% for clomifene. Droloxifene causes a dose-dependent decrease in luteinizing hormone and follicle-stimulating hormone levels, indicating that it has antigonadotropic activity, and dose-dependently increases sex hormone-binding globulin levels, indicating that it has estrogenic activity in the liver. Similarly to tamoxifen, droloxifene has partial estrogenic effects in the uterus. Unlike tamoxifen, droloxifene does not produce DNA adduct or liver tumors in animals. (en) |
| dbo:casNumber | 82413-20-5 |
| dbo:chEBI | 34731 |
| dbo:chEMBL | 487 |
| dbo:fdaUniiCode | 0M67U6Z98F |
| dbo:kegg | D03911 |
| dbo:pubchem | 3033767 |
| dbo:thumbnail | wiki-commons:Special:FilePath/Droloxifene.svg?width=300 |
| dbo:wikiPageExternalLink | http://webcache.googleusercontent.com/search%3Fq=cache:5syveMj6PR8J:adisinsight.springer.com/drugs/800000847+&cd=1&hl=en&ct=clnk&gl=us |
| dbo:wikiPageID | 52719931 (xsd:integer) |
| dbo:wikiPageLength | 7636 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1106900266 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Breast_cancer dbr:DNA_adduct dbr:Uterus dbr:Menopause dbc:Abandoned_drugs dbc:Dimethylamino_compounds dbc:Phenols dbr:Estrogen dbr:Oral_administration dbr:Endoxifen dbr:Germany dbr:Liver dbr:Structural_analogue dbr:Clinical_trial dbc:Hormonal_antineoplastic_drugs dbr:Triphenylethylene dbr:Afimoxifene dbr:Agonist dbc:Triphenylethylenes dbr:Estradiol_(medication) dbr:Estrogen_receptor dbr:Follicle-stimulating_hormone dbr:Nonsteroidal dbr:Osteoporosis dbc:Selective_estrogen_receptor_modulators dbr:International_Nonproprietary_Name dbr:Japan dbr:Tamoxifen dbr:Affinity_(pharmacology) dbr:Selective_estrogen_receptor_modulator dbr:United_States_Adopted_Name dbr:Liver_tumor dbr:Luteinizing_hormone dbr:Phases_of_clinical_research dbr:Sex_hormone-binding_globulin dbr:Antigonadotropic dbr:Cardiovascular_disorder |
| dbp:c | 26 (xsd:integer) |
| dbp:casNumber | 82413 (xsd:integer) |
| dbp:chebi | 34731 (xsd:integer) |
| dbp:chembl | 487 (xsd:integer) |
| dbp:chemspiderid | 2298372 (xsd:integer) |
| dbp:eliminationHalfLife | -133200.0 |
| dbp:h | 29 (xsd:integer) |
| dbp:iupacName | 3 (xsd:integer) |
| dbp:kegg | D03911 (en) |
| dbp:n | 1 (xsd:integer) |
| dbp:o | 2 (xsd:integer) |
| dbp:pubchem | 3033767 (xsd:integer) |
| dbp:routesOfAdministration | dbr:Oral_administration |
| dbp:smiles | CC/C/C3=CC=CC=C3 (en) |
| dbp:stdinchi | 1 (xsd:integer) |
| dbp:stdinchikey | ZQZFYGIXNQKOAV-OCEACIFDSA-N (en) |
| dbp:synonyms | FK-435; ICI-79280; K-060; K-21060E; RP-60850; 3-Hydroxytamoxifen; 3-OH-TAM (en) |
| dbp:unii | 0 (xsd:integer) |
| dbp:width | 250 (xsd:integer) |
| dbp:wikiPageUsesTemplate | dbt:Drugbox dbt:Estrogen_receptor_modulators dbt:Reflist dbt:Short_description |
| dcterms:subject | dbc:Abandoned_drugs dbc:Dimethylamino_compounds dbc:Phenols dbc:Hormonal_antineoplastic_drugs dbc:Triphenylethylenes dbc:Selective_estrogen_receptor_modulators |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment | Droloxifene (INN, USAN) (former developmental code names FK-435, ICI-79280, K-060, K-21060E, RP-60850), also known as 3-hydroxytamoxifen, is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group that was developed originally in Germany and later in Japan for the treatment of breast cancer, osteoporosis in men and postmenopausal women, and cardiovascular disorders but was abandoned and never marketed. It reached phase II and phase III clinical trials for these indications before development was discontinued in 2000. The drug was found to be significantly less effective than tamoxifen in the treatment of breast cancer in two phase III clinical trials. (en) |
| rdfs:label | Droloxifene (en) |
| owl:sameAs | yago-res:Droloxifene wikidata:Droloxifene https://global.dbpedia.org/id/2XtkV |
| prov:wasDerivedFrom | wikipedia-en:Droloxifene?oldid=1106900266&ns=0 |
| foaf:depiction | wiki-commons:Special:FilePath/Droloxifene.svg |
| foaf:isPrimaryTopicOf | wikipedia-en:Droloxifene |
| is dbo:wikiPageRedirects of | dbr:FK-435 dbr:FK435 dbr:FK_435 dbr:Droloxifen dbr:ICI-79,280 dbr:ICI-79280 dbr:ICI79,280 dbr:ICI79280 dbr:ICI_79,280 dbr:ICI_79280 dbr:K060 dbr:K21060E dbr:K_060 dbr:K_21060E dbr:RP-60,850 dbr:RP-60850 dbr:RP60,850 dbr:RP60850 dbr:RP_60,850 dbr:RP_60850 dbr:3-Hydroxytamoxifen dbr:3-hydroxytamoxifen dbr:K-060 dbr:K-21060E |
| is dbo:wikiPageWikiLink of | dbr:List_of_selective_estrogen_receptor_modulators dbr:Triphenylethylene dbr:Nonsteroidal dbr:C26H29NO2 dbr:FK-435 dbr:FK435 dbr:FK_435 dbr:IARC_group_3 dbr:List_of_drugs:_Dr–Dy dbr:Droloxifen dbr:ICI-79,280 dbr:ICI-79280 dbr:ICI79,280 dbr:ICI79280 dbr:ICI_79,280 dbr:ICI_79280 dbr:K060 dbr:K21060E dbr:K_060 dbr:K_21060E dbr:RP-60,850 dbr:RP-60850 dbr:RP60,850 dbr:RP60850 dbr:RP_60,850 dbr:RP_60850 dbr:3-Hydroxytamoxifen dbr:3-hydroxytamoxifen dbr:K-060 dbr:K-21060E |
| is foaf:primaryTopic of | wikipedia-en:Droloxifene |
